Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Lung deposition of formoterol HFA in healthy volunteers, asthmatic and COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 314s Year: 2005
Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Lung deposition of BDP/formoterol HFA pMDI in healthy subjects, asthmatic and COPD patients Source: Annual Congress 2008 - Imaging of different lung diseases: clinical and experimental observations Year: 2008
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Clinical equivalence of two HFA formulations of salmeterol xinafoate in asthmatic patients using 12 hour serial spirometry Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Effects on adrenal function of a new combination of fluticasone propionate/formoterol fumarate administered to asthmatic patients and healthy subjects Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010
Pharmacokinetic bioequivalence of inhaled CHF 1535 50/6 vs. the free combination of beclomethasone and formoterol in asthmatic children Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
The pharmacokinetics of inhaled NVA237 in COPD patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Population pharmacokinetics of nebulized arformoterol in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006
Comparative evaluation of formoterol budesonide combination MDI and salbutamol MDI for reversibility testing in patients with obstructive airways disease Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
High lung deposition of 99m Tc-labelled ciclesonide administered via HFA-MDI to asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 263s Year: 2001
Modulation of NK receptors by budesonide and/or formoterol in healthy volunteers and COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011